This incited the attempt to discontinue TKI treatment in CP-CML patients in 2-year long molecular remission defined as BCR–ABL/ABL levels lower than a detection threshold corresponded to a 5-log reduction [116]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.